Reduction of Influenza Virus Titer and Protection against Influenza Virus Infection in Infant Mice Fed<i>Lactobacillus casei</i>Shirota

  • Hisako Yasui
    Yakult Central Institute for Microbiological Research, 1796 Yaho, Kunitachi, Tokyo 186-8650, Japan
  • Junko Kiyoshima
    Yakult Central Institute for Microbiological Research, 1796 Yaho, Kunitachi, Tokyo 186-8650, Japan
  • Tetsuji Hori
    Yakult Central Institute for Microbiological Research, 1796 Yaho, Kunitachi, Tokyo 186-8650, Japan

抄録

<jats:title>ABSTRACT</jats:title><jats:p>We investigated whether oral administration of<jats:italic>Lactobacillus casei</jats:italic>strain Shirota to neonatal and infant mice ameliorates influenza virus (IFV) infection in the upper respiratory tract and protects against influenza infection. In a model of upper respiratory IFV infection, the titer of virus in the nasal washings of infant mice administered<jats:italic>L. casei</jats:italic>Shirota (<jats:italic>L. casei</jats:italic>Shirota group) was significantly (<jats:italic>P</jats:italic>< 0.05) lower than that in infant mice administered saline (control group) (10<jats:sup>2.48</jats:sup>± 10<jats:sup>0.31</jats:sup>and 10<jats:sup>2.78</jats:sup>± 10<jats:sup>0.4</jats:sup>, respectively). Further, the survival rate of the<jats:italic>L. casei</jats:italic>Shirota group was significantly (<jats:italic>P</jats:italic>< 0.05) higher than that of the control group (14.3 versus 40.0%). One day after infection, pulmonary NK cell activity and interleukin-12 production by mediastinal lymph node cells of mice in the<jats:italic>L. casei</jats:italic>Shirota group were significantly greater than those of mice in the control group. These findings suggest that oral administration of<jats:italic>L. casei</jats:italic>Shirota activates the immature immune system of neonatal and infant mice and protects against IFV infection. Therefore, oral administration of<jats:italic>L. casei</jats:italic>Shirota may accelerate the innate immune response of the respiratory tract and protect against various respiratory infections in neonates, infants, and children, a high risk group for viral and bacterial infections.</jats:p>

収録刊行物

被引用文献 (15)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ